| 8.1 Clinically relevant bleeding: DOAC vs placebo |
2 |
931 |
Risk Ratio (IV, Random, 95% CI) |
1.61 [0.82, 3.15] |
| 8.1.1 Apixaban |
1 |
122 |
Risk Ratio (IV, Random, 95% CI) |
1.87 [0.23, 14.91] |
| 8.1.2 Rivaroxaban |
1 |
809 |
Risk Ratio (IV, Random, 95% CI) |
1.58 [0.78, 3.21] |
| 8.2 Clinically relevant bleeding: LMWH vs no thromboprophylaxis |
4 |
3105 |
Risk Ratio (IV, Random, 95% CI) |
3.40 [1.20, 9.63] |
| 8.3 Clinically relevant bleeding: prophylactic vs intermediate vs therapeutic LMWH |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 8.3.1 Prophylactic vs intermediate |
1 |
51 |
Risk Ratio (IV, Fixed, 95% CI) |
Not estimable |
| 8.3.2 Prophylactic vs therapeutic |
1 |
52 |
Risk Ratio (IV, Fixed, 95% CI) |
0.33 [0.01, 7.82] |
| 8.4 Clinically relevant bleeding: semuloparin vs placebo |
1 |
3172 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [0.90, 2.19] |
| 8.5 Clinically relevant bleeding: UFH vs no thromboprophylaxis |
1 |
277 |
Risk Ratio (IV, Fixed, 95% CI) |
2.01 [0.18, 21.96] |
